J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal

Johnson & Johnson said it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than two years, boosting its presence in the market for brain disease treatments. The deal would help accelerate growth in J&J’s drugs business after the company spun off its consumer health unit in 2023.